Nathalie Mielcarek, Ph.D. , serves as a member of ILiAD’s Scientific Advisory Board. Dr. Mielcarek is a research director at the French National Institute of Health and Medical Research (Inserm). She is based at the Institut Pasteur de Lille (IPL), France where she leads since January 2020 the team "Research on Mycobacteria and Bordetella". Dr. Mielcarek has a long-standing interest and experience in infectious diseases and vaccine developmevnt. She obtained her PhD from the University of Lille, France in 1996 for her work on vaccine development against schistosomiasis at the Institut Pasteur de Lille (IPL). She then received a EU-funded Marie Curie fellowship to support her postdoctoral research on mucosal vaccination at the University of Göteborg, Sweden. In 2000, she returned to IPL to develop a novel nasal live attenuated vaccine against pertussis (BPZE1) which is currently under clinical development. From 2006 to 2009, she joined the International Vaccine Institute, in Seoul, South Korea where she initiated a research program on sublingual immunization against tuberculosis. Since her return to France, she coordinates international programs dedicated to preclinical and clinical developments of vaccines against whooping-cough and against tuberculosis. In 2020, she was appointed deputy director of the Center of Infection and Immunity of Lille (CIIL), gathering 14 teams around 2 transversal themes: i) Innovative anti-infective approaches and ii) Respiratory diseases. Nathalie Mielcarek is also the head of International Relations of the Institut Pasteur de Lille, hosting 32 research teams dedicated to infectious diseases, cancer, diabetes, cardiovascular and neurodegenerative diseases.